HOME >> MEDICINE >> NEWS
Predictors of undergoing joint replacement surgery among patients with severe osteoarthritis

A progressive, destructive joint disease, osteoarthritis (OA) is a major cause of disability worldwide. Total joint arthroplasty (TJA) is a highly successful and cost-effective procedure for managing OA of the hip and knee. Despite this, analyses of hospital records show variations in the rates of TJA by region, gender, race, and socioeconomic status. While these studies tell us about who is undergoing hip and knee replacement surgery, what's missing is why--a comprehensive, rigorous examination of the predisposing factors affecting TJA rates.

Why do some arthritis sufferers agree to undergo TJA and others resist it? To examine the predictors of time to a first TJA, a team of Canadian researchers, affiliated with the University of Toronto and other research institutes, conducted a population-based study of 2,128 individuals ages 55 and over with disabling OA of the hip and/or knee. Their findings, featured in the October 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), support the need for community-based education about arthritis treatments, including hip and knee replacement surgery.

This groundbreaking study focused on two regions of Ontario--one rural with high rates of TJA and one urban with low rates. It started in 1999 with an established sample of older citizens--1,158 from the country; 970 from the city--with severe hip and/or knee OA and no prior joint replacement. Researchers devoted 7 years to follow up, consisting of annual surveys and check-ups on disease progression, linked with hospital databases to determine whether patients had undergone hip or knee replacement surgery.

Among the study population, 73 percent were women, 96 percent were white, 31 percent were living alone, independently, and nearly 68 percent had a high school education or higher. At baseline,
'"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
28-Sep-2006


Page: 1 2 3

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Should patients undergoing surgery get ASA?
3. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
4. Women with endometriosis undergoing IVF benefit from treatment with GnRH agonists
5. Distant prayer does not improve clinical outcome for patients undergoing coronary procedures
6. Patients may want to skip that cup of coffee before undergoing PET/CT scans
7. New methods offer alternatives for patients undergoing obesity surgery
8. Vicente Fox Center and RAND launch joint program to find policies to combat poverty
9. Experimental gene therapy abolishes arthritis pain and lessens joint damage
10. Slick and springy: Brown research reveals proteins role in joints
11. Key study offers hope to patients with lung and joint disease

Post Your Comments:
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
Cached News: